The first patient has been enrolled in OssDsign’s multi-center, prospective spinal fusion registry in the U.S., PROPEL, with the objective to evaluate the use and outcome of OssDsign Catalyst in real-world clinical practice.
OssDsign Catalyst is a synthetic bone graft designed to help promote bone growth in spinal fusions. Similar to the body’s own bone mineral structure, the patented nanocrystalline structure of OssDsign Catalyst provides a bone biology environment intended to induce rapid and reliable bone formation. The product received FDA clearance in 2020 and was launched on the U.S. market in August 2021.
PROPEL will initially evaluate the rate of fusion twelve months following treatment with OssDsign Catalyst. Additionally, the clinical safety profile, as well as the patient’s quality of life and neurological function will be recorded. OssDsign expects to include several more clinical sites to the registry over the coming quarters.
“We are very pleased that the process of adding clinical sites and enrolling patients to PROPEL has been achieved according to plan. The registry is one of the core pillars in our long-term strategy and will, over time, generate a large amount of relevant data on both performance and safety of OssDsign Catalyst. Through the registry we will also have a close and continuous dialogue with surgeons, which is invaluable during our ongoing launch of OssDsign Catalyst in the U.S.,” said Morten Henneveld, CEO, OssDsign.
The first patient has been enrolled in OssDsign's multi-center, prospective spinal fusion registry in the U.S., PROPEL, with the objective to evaluate the use and outcome of OssDsign Catalyst in real-world clinical practice.
OssDsign Catalyst is a synthetic bone graft designed to help promote bone growth in spinal fusions. Similar to the body’s...
The first patient has been enrolled in OssDsign’s multi-center, prospective spinal fusion registry in the U.S., PROPEL, with the objective to evaluate the use and outcome of OssDsign Catalyst in real-world clinical practice.
OssDsign Catalyst is a synthetic bone graft designed to help promote bone growth in spinal fusions. Similar to the body’s own bone mineral structure, the patented nanocrystalline structure of OssDsign Catalyst provides a bone biology environment intended to induce rapid and reliable bone formation. The product received FDA clearance in 2020 and was launched on the U.S. market in August 2021.
PROPEL will initially evaluate the rate of fusion twelve months following treatment with OssDsign Catalyst. Additionally, the clinical safety profile, as well as the patient’s quality of life and neurological function will be recorded. OssDsign expects to include several more clinical sites to the registry over the coming quarters.
“We are very pleased that the process of adding clinical sites and enrolling patients to PROPEL has been achieved according to plan. The registry is one of the core pillars in our long-term strategy and will, over time, generate a large amount of relevant data on both performance and safety of OssDsign Catalyst. Through the registry we will also have a close and continuous dialogue with surgeons, which is invaluable during our ongoing launch of OssDsign Catalyst in the U.S.,” said Morten Henneveld, CEO, OssDsign.
Copy to clipboard 
